Effectivity of treatment for children with functional dyspepsia

Corinne Légeret1, Yvonne Stienen2,3, Raoul Furlano2

  • 1University Children's Hospital of Basel, Spitalstrasse, 4055, Basel, Switzerland. Corinne.Legeret@bluewin.ch.

Scientific Reports
|January 28, 2022
PubMed

Insights

Functional dyspepsia in children is common, impacting quality of life. While treatments vary, reassurance and lifestyle advice appear most beneficial, rather than specific interventions.

Area of Science:

  • Pediatric Gastroenterology
  • Functional Gastrointestinal Disorders
  • Quality of Life Research

Background:

  • Functional dyspepsia (FD) is highly prevalent in children, significantly affecting their lives and families.
  • The Rome IV criteria's revised subtypes have increased FD diagnoses, yet treatment guidelines remain absent.
  • Understanding FD patient characteristics and treatment outcomes is crucial for developing effective management strategies.

Purpose of the Study:

  • To characterize pediatric patients diagnosed with functional dyspepsia.
  • To analyze the outcomes of various treatments administered to these patients.
  • To identify potential correlations between treatments, patient demographics, and symptom duration.

Main Methods:

  • Retrospective study of 154 pediatric patients (aged 4-18) diagnosed with FD between March 2017 and September 2020.
  • Inclusion criteria: gastric symptoms, normal blood count, thyroid function, celiac screening, and esophagogastroduodenoscopy.
  • Data collection via medical records; parent interviews conducted three months post-endoscopy to assess treatment effects.

Main Results:

  • Epigastric pain was the leading symptom (73.4%), followed by nausea (14.3%).
  • Treatments included STW5 (32.3%), psychological support (22.7%), alternative therapies (19.5%), dietary changes (12.9%), and lifestyle changes (9.7%).
  • Lifestyle changes in females, dietary changes in girls, and STW5 in males showed statistically significant correlations with symptom duration.

Conclusions:

  • No correlation was found between symptom location and treatment effectiveness.
  • Patients may benefit more from diagnosis education, reassurance, and lifestyle recommendations than specific treatments.
  • Individualized approaches considering psychological support or alternative therapies may be beneficial, but success is unpredictable.

Related Concept Videos

Gastroesophageal Reflux Disease II: Clinical Features and Management01:29

Gastroesophageal Reflux Disease II: Clinical Features and Management

Gastroesophageal reflux disease, or GERD, is a persistent medical condition that affects many individuals worldwide. Its clinical manifestations can vary greatly, making diagnosis and management challenging for healthcare professionals. The following is a comprehensive overview of the clinical manifestations, assessment, and management strategies for GERD.
Clinical Manifestations
GERD presents itself in a multitude of ways, with symptoms varying from person to person. The hallmark symptoms are...
239
Peptic Ulcer Disease IV: Management01:26

Peptic Ulcer Disease IV: Management

Medical treatment strategies for peptic ulcers encompass various methods. The primary goal of treatment is to diminish gastric acidity and strengthen mucosal defense mechanisms.
The therapeutic approach involves ensuring adequate rest, implementing drug therapy, promoting smoking cessation, making dietary modifications, and emphasizing long-term follow-up care.
Pharmacological management
The prevailing therapy for peptic ulcers involves a combination of managing the patient's current...
157
Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption01:23

Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption

Understanding the physiological differences in the pediatric population is crucial for effective pharmacotherapy. Neonates, infants, and children exhibit significant variations in gastric pH, gastric emptying time, intestinal transit time, and biliary function. These variations profoundly affect oral drug absorption, necessitating a nuanced approach to pediatric dosing.Neonates present with a unique physiological profile, having a gastric pH greater than 4 and faster and more irregular gastric...
12
Treating Helicobacter pylori in Peptic Ulcers: Antimicrobial Therapy01:16

Treating Helicobacter pylori in Peptic Ulcers: Antimicrobial Therapy

Helicobacter pylori, a resilient gram-negative bacterium, can thrive in the stomach's harsh, acidic environment. Infection with H. pylori leads to a cascade of events within the stomach lining. One of the critical disruptions caused by this bacterium is the interference with somatostatin production, a hormone responsible for regulating acid secretion. This interference tips the balance, escalating acid secretion and diminishing bicarbonate levels. This imbalance compromises the defensive...
609
Drugs for Treatment of Constipation-Predominant IBS01:21

Drugs for Treatment of Constipation-Predominant IBS

Pharmacological therapies for IBS-C are designed to alleviate abdominal discomfort and enhance bowel function. In patients with IBS-C, fiber supplements may help soften stools and decrease straining, but may also lead to increased gas production and bloating. Osmotic laxatives like milk of magnesia are frequently used to soften stools and increase stool frequency in IBS-C patients. In addition, two drugs approved for use in severe IBS-C adult cases are linaclotide (Linzess) and lubiprostone...
371
Pharmacokinetics in Pediatric Patients: Drug Metabolism01:24

Pharmacokinetics in Pediatric Patients: Drug Metabolism

In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses...
17